Elixir Pharmaceuticals

Elixir Pharmaceuticals
Cambridge, Mass.
Founded: 1999

Why It's Fierce: Elixir Pharmaceuticals is developing drugs to regulate recently discovered longevity genes. While the company is at least a decade from introducing its first product, research in worms suggests altering a single gene can delay the onset of age-related diseases such as obesity and type-II diabetes. Last month Elixir merged with cross-town rival Centagenetix, combining the top scientists in this clubby niche. A fresh $17 million cash infusion should nourish additional preclinical work. This is probably the most speculative pick in this year's list. We hope our optimism is justified.

What to look for in 2003: Combining scientists from Centagenetix and Elixir will accelerate research of longevity genes.

Elixir Pharmaceuticals

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.